ImmuPharma PLC (IMM) Receives “Buy” Rating from Northland Securities
Northland Securities reissued their buy rating on shares of ImmuPharma PLC (LON:IMM) in a research note issued to investors on Thursday morning. The brokerage currently has a GBX 181 ($2.44) target price on the stock.
ImmuPharma PLC (LON:IMM) traded down 1.98% during trading on Thursday, reaching GBX 49.50. The company’s stock had a trading volume of 26,187 shares. The firm has a 50 day moving average price of GBX 49.53 and a 200-day moving average price of GBX 52.68. ImmuPharma PLC has a 52-week low of GBX 31.44 and a 52-week high of GBX 70.32. The stock’s market cap is GBX 65.60 million.
TRADEMARK VIOLATION NOTICE: “ImmuPharma PLC (IMM) Receives “Buy” Rating from Northland Securities” was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/22/immupharma-plc-imm-receives-buy-rating-from-northland-securities.html.
About ImmuPharma PLC
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.